MCID: LVR013
MIFTS: 75

Liver Disease malady

Categories: Gastrointestinal diseases, Liver diseases, Genetic diseases, Rare diseases, Metabolic diseases

Aliases & Classifications for Liver Disease

Summaries for Liver Disease

MedlinePlus : 41 your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. there are many kinds of liver diseases: diseases caused by viruses, such as hepatitis a, hepatitis b, and hepatitis c diseases caused by drugs, poisons, or too much alcohol. examples include fatty liver disease and cirrhosis. liver cancer inherited diseases, such as hemochromatosis and wilson disease symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. sometimes there are no symptoms. tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to congenital dyserythropoietic anemia and hereditary hemorrhagic telangiectasia, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Liver Disease is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Folate Metabolism and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Ursodeoxycholic acid and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and bone, and related phenotypes are homeostasis/metabolism and behavior/neurological

Wikipedia : 71 Liver disease (also called hepatic disease) is a type of damage to or disease of the... more...

Related Diseases for Liver Disease

Diseases in the Liver Disease family:

Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 1
Liver Failure, Transient Infantile Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)
id Related Disease Score Top Affiliating Genes
1 congenital dyserythropoietic anemia 31.3 ALB TNF
2 hereditary hemorrhagic telangiectasia 29.7 AFP F2 GGT1 GPT SLC17A5 TNF
3 obstructive jaundice 29.7 ALB F2 TNF
4 b-cell lymphomas 29.6 DLAT F2 GGT1 GPT
5 megaloblastic anemia 29.4 F3 GPT SLC17A5
6 meningitis 29.3 ADIPOQ CYP2E1 INS LEP PPARA SLC17A5
7 membranoproliferative glomerulonephritis 29.3 ALB F2 F3 TNF
8 pericarditis 29.1 ADIPOQ ALB F3 INS
9 fatty liver disease 12.4
10 polycystic liver disease 12.4
11 fatty liver disease, nonalcoholic 1 12.1
12 interstitial lung and liver disease 12.0
13 polycystic kidney and hepatic disease 11.9
14 dystonia/parkinsonism, hypermanganesemia, polycythemia, and chronic liver disease 11.9
15 fatty liver disease, nonalcoholic 2 11.7
16 pnpla3-related susceptibility to nonalchoholic fatty liver disease 11.7
17 recurrent hepatitis c virus induced liver disease in liver transplant recipients 11.7
18 nonalcoholic steatohepatitis 11.7
19 alcoholic hepatitis 11.6
20 mitochondrial dna depletion syndrome 4a 11.5
21 wilson disease 11.1
22 cholestasis, progressive familial intrahepatic 1 11.1
23 hemochromatosis 11.0
24 bile acid synthesis defect, congenital, 4 11.0
25 bile acid synthesis defect, congenital, 1 11.0
26 hepatitis c 11.0
27 hepatic vascular disease 10.9
28 bile acid synthesis defect, congenital, 2 10.9
29 hepatopulmonary syndrome 10.8
30 hepatorenal syndrome 10.8
31 hypermanganesemia with dystonia, polycythemia, and cirrhosis 10.8
32 emphysema due to aat deficiency 10.8
33 acute liver failure 10.8
34 hepatic encephalopathy 10.8
35 dysfibrinogenemia 10.8
36 alagille syndrome 10.8
37 hypobetalipoproteinemia 10.8
38 congenital hepatic fibrosis 10.8
39 melioidosis 10.8
40 bile duct carcinoma 10.8
41 protein c deficiency 10.8
42 fructose intolerance 10.8
43 immunodeficiency, primary, autosomal recessive, il21r-related 10.7
44 visceral steatosis 10.7
45 mpv17-related hepatocerebral mitochondrial dna depletion syndrome 10.7
46 mitochondrial complex i deficiency 10.7
47 glycogen storage disease iv 10.7
48 hepatitis 10.6
49 reynolds syndrome 10.6
50 cirrhosis, cryptogenic 10.6

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Ischemic Heart Disease
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease

Symptoms & Phenotypes for Liver Disease

UMLS symptoms related to Liver Disease:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, hepatosplenomegaly, icterus, nausea and vomiting, liver tender, digestive system symptom, gastrointestinal gas, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ABCB11 ADIPOQ AFP ALB CP CYP2E1
2 behavior/neurological MP:0005386 10.27 CP CYP2E1 F2 F3 GGT1 INS
3 cellular MP:0005384 10.23 ADIPOQ ALB CP F3 FAH HGF
4 growth/size/body region MP:0005378 10.21 ABCB11 ADIPOQ F2 F3 FAH GGT1
5 cardiovascular system MP:0005385 10.18 LEP PPARA TNF ADIPOQ CP CYP2E1
6 mortality/aging MP:0010768 10.16 F3 FAH GGT1 HGF INS LEP
7 liver/biliary system MP:0005370 10.13 HGF INS LEP PPARA PRKCSH TNF
8 integument MP:0010771 9.97 LEP PPARA TNF ADIPOQ F2 F3
9 neoplasm MP:0002006 9.76 ADIPOQ AFP ALB CYP2E1 F3 FAH
10 renal/urinary system MP:0005367 9.5 ADIPOQ ALB FAH GGT1 INS LEP
11 vision/eye MP:0005391 9.23 ABCB11 CP F3 GGT1 INS LEP

Drugs & Therapeutics for Liver Disease

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1184)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128-13-2 31401
2
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
3
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
4
Caspofungin Approved Phase 4,Phase 2 179463-17-3, 162808-62-0 468682 2826718
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
6
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1 57-27-2 5288826
7
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
8
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
9
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
10
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
11
Magnesium oxide Approved Phase 4 1309-48-4 14792
12
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
13
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
14
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
15
Insulin-glulisine Approved Phase 4 207748-29-6
16
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
17
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1 4618-18-2 11333
18
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
19
Colchicine Approved Phase 4,Phase 3,Phase 2,Phase 1 64-86-8 6167 2833
20
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
21
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
22
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
23
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
24
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
25
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
26
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
27
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80621-81-4 6436173
28
Erythromycin Approved, Vet_approved Phase 4,Phase 1 114-07-8 12560
29
Simvastatin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 79902-63-9 54454
30
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2 2216-51-5 16666
31
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
32
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
33
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3 525-66-6 4946
34
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
35
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 142340-99-6 60871
36
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
37
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2 72956-09-3 2585
38
Amlodipine Approved Phase 4 88150-42-9 2162
39
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
40
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 26787-78-0 33613 2171
41
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 53477736 447043
42
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
43
Cefoxitin Approved Phase 4 35607-66-0 441199
44
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Early Phase 1 85721-33-1 2764
45
Imipenem Approved Phase 4 74431-23-5 104838
46
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
47
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
48
Nitric Oxide Approved Phase 4,Phase 2,Phase 1 10102-43-9 145068
49
Prazosin Approved Phase 4,Phase 2 19216-56-9 4893
50
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385

Interventional clinical trials:

(show top 50) (show all 5476)
id Name Status NCT ID Phase
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4
2 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
3 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4
4 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4
5 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Unknown status NCT01968395 Phase 4
6 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme Unknown status NCT01429779 Phase 4
7 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4
8 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4
9 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4
10 A Study of Thymoglobulin and Tacrolimus in Liver Transplant Unknown status NCT00564538 Phase 4
11 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4
12 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4
13 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4
14 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
15 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4
16 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
17 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4
18 Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity Unknown status NCT00878592 Phase 4
19 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4
20 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4
21 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4
22 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
23 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4
24 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4
25 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4
26 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4
27 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4
28 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4
29 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4
30 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4
31 Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc) Unknown status NCT00736463 Phase 4
32 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4
33 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4
34 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
35 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4
36 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4
37 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4
38 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4
39 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4
40 Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding Unknown status NCT00965900 Phase 4
41 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4
42 Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline Unknown status NCT00343122 Phase 4
43 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4
44 RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4
45 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4
46 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4
47 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
48 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4
49 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4
50 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver diseases

Genetic Tests for Liver Disease

Genetic tests related to Liver Disease:

id Genetic test Affiliating Genes
1 Hepatic Failure 29
2 Abnormality of the Liver 29

Anatomical Context for Liver Disease

MalaCards organs/tissues related to Liver Disease:

39
Liver, Testes, Bone, Kidney, Skin, Eye, Endothelial

Publications for Liver Disease

Articles related to Liver Disease:

(show top 50) (show all 3732)
id Title Authors Year
1
An update on the pathophysiology and management of polycystic liver disease. ( 28317394 )
2017
2
Liver Transplantation for Polycystic Liver Disease Due to Huge Liver With Related Complications: A Case Report. ( 28340841 )
2017
3
Changes in the Prevalence of Hepatitis C Virus Infection, Non-alcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. ( 28088461 )
2017
4
Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by (18)F-fluorodeoxyglucose positron emission tomography. ( 28081780 )
2017
5
Re: Bleeding Risk and Management in Interventional Procedures in Chronic Liver Disease. ( 28532751 )
2017
6
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. ( 28521870 )
2017
7
Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease. ( 28521774 )
2017
8
An endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of Kupffer cell polarization. ( 28090670 )
2017
9
Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study. ( 28081779 )
2017
10
QT prolongation is associated with increased mortality in end stage liver disease. ( 28515853 )
2017
11
Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. ( 27910154 )
2017
12
Modulation of the gut microbiota impacts non-alcoholic fatty liver disease: a potential role for bile acids. ( 28533304 )
2017
13
Polycystic Liver Disease and Sarcoidosis: Unusual Coexisting Etiologies of Portal Hypertension. ( 28280650 )
2017
14
The PNPLA3 Variant Associated with Fatty Liver Disease (I148M) Accumulates on Lipid Droplets by Evading Ubiquitylation. ( 28520213 )
2017
15
Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. ( 28086768 )
2017
16
Endocrine-disrupting chemicals and fatty liver disease. ( 28524171 )
2017
17
Grand Round: Anticoagulation in Chronic Liver Disease. ( 28088580 )
2017
18
Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. ( 27908400 )
2017
19
Identification of Potential Plasma Biomarkers for Nonalcoholic Fatty Liver Disease by Integrating Transcriptomics and Proteomics in Laying Hens. ( 28077733 )
2017
20
High free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independently of obesity and insulin resistance. ( 28487551 )
2017
21
Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice. ( 28056490 )
2017
22
Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. ( 28075394 )
2017
23
Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. ( 28214926 )
2017
24
Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients. ( 28473851 )
2017
25
Author Reply-Bariatric Surgery and Liver Function Tests in Nonalcoholic Fatty Liver Disease. ( 28091895 )
2017
26
Isolated polycystic liver disease genes define effectors of polycystin-1 function. ( 28375157 )
2017
27
Metabolic effects of Crocus sativus and protective action against non-alcoholic fatty liver disease in diabetic rats. ( 28529733 )
2017
28
Hepatobiliary and Pancreatic: A unique case of HPV related metastatic Schneiderian carcinoma presenting as polycystic liver disease. ( 28052462 )
2017
29
Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. ( 28533672 )
2017
30
Center is an important indicator for choice of invasive therapy in polycystic liver disease. ( 27732751 )
2017
31
Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. ( 28521872 )
2017
32
Waitlisted Candidates With Polycystic Liver Disease are More Likely to be Transplanted Than Those With Chronic Liver Failure. ( 28296808 )
2017
33
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease. ( 28092906 )
2017
34
Bariatric Surgery and Liver Function Tests in Nonalcoholic Fatty Liver Disease. ( 28091896 )
2017
35
The relationship of nonalcoholic fatty liver disease and metabolic syndrome for colonoscopy colorectal neoplasm. ( 28079806 )
2017
36
An extended fatty liver index to predict non-alcoholic fatty liver disease. ( 28089502 )
2017
37
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. ( 28526997 )
2017
38
Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. ( 28326329 )
2017
39
Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. ( 28533673 )
2017
40
Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. ( 28055049 )
2017
41
Gene-metabolite network analysis in different nonalcoholic fatty liver disease phenotypes. ( 28082742 )
2017
42
Esculetin ameliorates hepatic fibrosis in high fat diet induced non-alcoholic fatty liver disease by regulation of FoxO1 mediated pathway. ( 28527877 )
2017
43
Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply. ( 28074505 )
2017
44
Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease. ( 28206970 )
2017
45
Insulin-like growth factor 1 and metabolic parameters are associated with nonalcoholic fatty liver disease in obese children and adolescents. ( 27889912 )
2017
46
Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. ( 27995687 )
2017
47
Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome. ( 28527304 )
2017
48
Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia. ( 28074504 )
2017
49
Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. ( 28523578 )
2017
50
P-selectin, endocan, and some adhesion molecules in obese children and adolescents with non-alcoholic fatty liver disease. ( 28318371 )
2017

Variations for Liver Disease

Expression for Liver Disease

Search GEO for disease gene expression data for Liver Disease.

Pathways for Liver Disease